2008
DOI: 10.1055/s-0028-1083807
|View full text |Cite
|
Sign up to set email alerts
|

Focal Nodular Hyperplasia in Children Following Treatment of Hemato-Oncologic Diseases

Abstract: Diagnosis of FNH has to be included in the differential diagnosis of uncertain liver lesions. Biopsy might be avoided by using special imaging techniques like MRI, CT and ultrasound. A wait and see strategy is recommended, specific treatment is not necessary.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2009
2009
2016
2016

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(5 citation statements)
references
References 7 publications
0
5
0
Order By: Relevance
“…Benign hepatic lesions are rare entities in childhood but some of them have been reported more frequently in children with a history of malignancy after cancer treatment (1,2). An increased prevalence of focal nodular hyperplasia (FNH) has been reported in children after chemoradiation therapy (1)(2)(3)(4) especially after hematopoietic stem cell transplantation (HSCT) (5)(6)(7). Nodular regenerative hyperplasia (NRH) has also been reported as a rare sequela of antineoplastic therapy (8)(9)(10)(11).…”
mentioning
confidence: 99%
“…Benign hepatic lesions are rare entities in childhood but some of them have been reported more frequently in children with a history of malignancy after cancer treatment (1,2). An increased prevalence of focal nodular hyperplasia (FNH) has been reported in children after chemoradiation therapy (1)(2)(3)(4) especially after hematopoietic stem cell transplantation (HSCT) (5)(6)(7). Nodular regenerative hyperplasia (NRH) has also been reported as a rare sequela of antineoplastic therapy (8)(9)(10)(11).…”
mentioning
confidence: 99%
“…In the general pediatric population, an annual incidence of FNH of 0.02% has been estimated and a significant percentage of the pediatric cases are described in children with a history of malignant disease treated with chemo‐radiation therapy or in children given HSCT . The use of high‐dose alkylating agents during a myeloablative conditioning regimen and complications targeting endothelial cells, such as GVHD, SOS, and thrombotic microangiopathy together with other variables linked to the HSCT procedure can represent risk factors for the development of FNH in the pediatric age .…”
mentioning
confidence: 99%
“…FNH is an uncommon occurrence in the pediatric population, accounting for 2% of all hepatic tumors and 5% of all FNHs 18. Several associations have been made with FNH in this population, including stem cell transplantion19 and chemotherapeutic and radiation treatment of hemato‐oncological disease 13, 20, 21. The aforementioned treatments and/or associated diseases are likely contributing to altered hepatic vascular perfusion, predisposing patients to the formation of FNH.…”
Section: Discussionmentioning
confidence: 99%